Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 50 of 1886 results for carers

  1. NICE Listens

    Programme develops and supports the participation of people who use services, carers and members of the public, along with the...

  2. Highly specialised technologies evaluation committee

    appointed for a 3-year term, and are drawn from: the NHS patient and carer organisations academia pharmaceuticals and medical device...

  3. Interventional procedures advisory committee

    Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.

  4. Endometriosis: diagnosis and management (NG73)

    This guideline covers diagnosing and managing endometriosis. It aims to raise awareness of the symptoms of endometriosis, and to provide clear advice on what action to take when women and people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

  5. Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema (IPG785)

    Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.

  6. Our projects and partners

    NICE research projects and partners.

  7. Technology appraisal committee

    Details, meeting dates and minutes of the independent technology appraisal committees

  8. Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

    Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

  9. Twin and triplet pregnancy (NG137)

    This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.

  10. Help us improve

    Help us improve NICE: take part in research to help us develop better products and services.

  11. Technology appraisal submission templates and supporting documents

    confidential information (Word) Other stakeholder templates Patient carer organisation (Word) Professional organisation (Word)...

  12. Overview: how we develop technology appraisal guidance

    Consultee organisations include: national groups representing patients and carers bodies representing healthcare professionals the...

  13. Using NICE guidance in social work

    A range of fictional scenarios which show how NICE's guidelines and quality standards could be used by social workers in different settings.

  14. Support a quality standard

    Find out more about supporting a quality standard at NICE.

  15. Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

    Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.

  16. Our charter

    An outline of the roles and responsibilities of the National Institute for Health and Care Excellence

  17. Medical technologies advisory committee members

    a non-executive director of a primary care trust, Emily involved users, carers, and community organisations in developing quality...

  18. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

  19. Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)

    Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.

  20. Suspected sepsis: recognition, diagnosis and early management (NG51)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  21. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.

  22. Neonatal infection: antibiotics for prevention and treatment (NG195)

    This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.

  23. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  24. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  25. Guides to developing our guidance

    Resources to help organisations who want to help develop NICE guidance

  26. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.

  27. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  28. NICE publishes final draft guidance on Enhertu after commercial discussions conclude without a price to make it a cost-effective use of NHS resources.

    NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.

  29. Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)

    This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.

  30. Our committees

    Find out more about being on a committee at NICE.

  31. Achieving and demonstrating compliance with NICE TA and HST guidance

    NICE guidance in the delivery of care means for patients, service users and carers Children, young people and adults will have access to...

  32. Patient decision aids

    Information to help people living with dementia, their family members and carers and their healthcare professionals discuss the options....

  33. Diagnostics advisory committee

    that assessment. Committee members are drawn from: the NHS patient and carer organisations academia the diagnostics industry. Although...

  34. Implementing NICE guidance

    Putting our guidance into practice benefits patients and carers, healthcare professionals and organisations. Teams within NICE have a...

  35. NICE voluntary and community sector forum

    organisations for people who use health and social care services, their families and carers, and the public local Healthwatch...

  36. Tuberculosis (NG33)

    This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.

  37. Digitally enabled therapies for adults with depression: early value assessment (HTE8)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....

  38. Join the public involvement programme expert panel

    Join Nice's Public Involvement Programme expert panel

  39. Appeal panel membership

    the UK someone with experience in representing patients or carers, or who is a patient or carer (patient representative)....

  40. Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

    Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.

  41. Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

    Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.

  42. Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)

    Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.

  43. Indicator advisory committee (IAC)

    health and social care professionals patients or service users and their carers academics. They do not represent their organisations but...

  44. Maintaining and updating our guideline portfolio

    topic experts, including: health and care professionals patients and carers. Each committee will provide us with vital intelligence on...

  45. Quick guides to social care topics

    A quick, easy way to access key information from NICE on social care topics.

  46. Committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  47. Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (TA947)

    Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.

  48. Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)

    Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.

  49. Caesarean birth (NG192)

    This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.